FDA Drug Shortage Database
Furosemide (Lasix) shortage
The FDA Drug Shortage Database lists 12 of 32 furosemide presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on April 7, 2020. 17 more presentations are on the list as available.
- Generic listed
- In shortage
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 10mg/1ml injection | 7 | 10 | 3 |
| 10mg/1ml solution | 1 | 1 | 0 |
| 20mg/2ml injection | 2 | 1 | 0 |
| 40mg/4ml injection | 1 | 2 | 0 |
| 40mg/5ml solution | 0 | 1 | 0 |
| 100mg/10ml injection | 1 | 2 | 0 |
Which presentations are listed?
Limited or unavailable now (12)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08) | Accord Healthcare Inc. | Current posted April 7, 2020, updated October 3, 2026 | Unavailable; Requirements related to complying with good manufacturing practices |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43) | Accord Healthcare Inc. | Current posted April 7, 2020, updated October 3, 2026 | Unavailable; Requirements related to complying with good manufacturing practices |
| Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43) | Accord Healthcare Inc. | Current posted April 7, 2020, updated October 3, 2026 | Unavailable; Requirements related to complying with good manufacturing practices |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44) | Avet Pharmaceuticals, Inc. | Current posted April 7, 2020, updated October 5, 2026 | Unavailable; Other |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | Gland Pharma Limited | Current posted April 7, 2020, updated July 22, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | Gland Pharma Limited | Current posted April 7, 2020, updated July 22, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) | Gland Pharma Limited | Current posted April 7, 2020, updated July 22, 2026 | Unavailable; Discontinuation of the manufacture of the drug |
| Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Unavailable; Other |
| Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Unavailable; Other |
| Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25) | Eugia US LLC | Current posted April 7, 2020, updated October 2, 2026 | Unavailable; Demand increase for the drug |
| Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Unavailable; Other |
| Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50) | Hikma Pharmaceuticals USA, Inc. | Current posted March 31, 2026, updated September 18, 2026 | Limited Availability; Shortage of an inactive ingredient component |
Listed now, available (17)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41) | Avet Pharmaceuticals, Inc. | Current posted April 7, 2020, updated October 5, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42) | Avet Pharmaceuticals, Inc. | Current posted April 7, 2020, updated October 5, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25) | Baxter Healthcare | Current posted April 7, 2020, updated October 2, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25) | Baxter Healthcare | Current posted April 7, 2020, updated October 2, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25) | Baxter Healthcare | Current posted April 7, 2020, updated October 2, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02) | Fresenius Kabi USA, LLC | Current posted April 7, 2020, updated October 6, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04) | Fresenius Kabi USA, LLC | Current posted April 7, 2020, updated October 6, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10) | Fresenius Kabi USA, LLC | Current posted April 7, 2020, updated October 6, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05) | Meitheal Pharmaceuticals, Inc. | Current posted April 7, 2020, updated August 27, 2026 | Available |
| Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11) | Meitheal Pharmaceuticals, Inc. | Current posted April 7, 2020, updated August 27, 2026 | Available |
| Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Available |
| Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25) | Eugia US LLC | Current posted April 7, 2020, updated October 2, 2026 | Available |
| Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Available |
| Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04) | Hospira, Inc., a Pfizer Company | Current posted April 7, 2020, updated September 22, 2026 | Available |
| Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25) | Eugia US LLC | Current posted April 7, 2020, updated October 2, 2026 | Available |
| Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46) | Hikma Pharmaceuticals USA, Inc. | Current posted March 31, 2026, updated September 18, 2026 | Available; Shortage of an inactive ingredient component |
| Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63) | Hikma Pharmaceuticals USA, Inc. | Current posted March 31, 2026, updated September 18, 2026 | Available; Shortage of an inactive ingredient component |
Resolved or discontinued (3)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02) | Gland Pharma Limited | To Be Discontinued posted April 28, 2026, updated April 28, 2026 | not given |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04) | Gland Pharma Limited | To Be Discontinued posted April 28, 2026, updated April 28, 2026 | not given |
| Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10) | Gland Pharma Limited | To Be Discontinued posted April 28, 2026, updated April 28, 2026 | not given |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Bumetanide | Heart failure | Resolved | 36 labelers | $0.108 per tablet 1 mg tablet |
| Torsemide | High blood pressure, Heart failure | No current entry | 20 labelers | $0.0636 per tablet 20 mg tablet |
| Ethacrynic acid | Heart failure | No current entry | 10 labelers | $0.807 per tablet 25 mg tablet |
| Metoprolol | High blood pressure, Heart failure | A presentation being discontinued | 74 labelers | $0.085 per tablet 100 mg tablet |
| Lisinopril | High blood pressure, Heart failure | No current entry | 36 labelers | $0.0254 per tablet 20 mg tablet |
| Carvedilol | High blood pressure, Heart failure | No current entry | 41 labelers | $0.0179 per tablet 6.25 mg tablet |
| Spironolactone | High blood pressure, Heart failure | A presentation being discontinued | 38 labelers | $0.0426 per tablet 25 mg tablet |
| Hydrochlorothiazide | High blood pressure, Heart failure | A presentation being discontinued | 43 labelers | $0.0115 per tablet 25 mg tablet |
| Valsartan | High blood pressure, Heart failure | A presentation being discontinued | 34 labelers | $0.0963 per tablet 40 mg tablet |
| Enalapril | High blood pressure, Heart failure | No current entry | 28 labelers | $0.0664 per tablet 10 mg tablet |
| Chlorthalidone | High blood pressure, Heart failure | No current entry | 36 labelers | $0.0743 per tablet 25 mg tablet |
| Sacubitril and valsartan | Heart failure | No current entry | 27 labelers | $0.533 per unit 49-51 mg |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage